Transcriptomics

Dataset Information

0

Phase Ib/II Study of Azacitidine, Venetoclax and Magrolimab in Adult Patients with Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia

ABSTRACT: To better understand the mechanisms of response and resistance to azacitdine, venetoclax, and magrolimab (AVM), we performed single-cell RNA-sequencing (scRNAseq) on 27 samples (11 pre- and 16 post-treatment) from 11 TP53-mutated patients with combined therapy

ORGANISM(S): Homo sapiens

PROVIDER: GSE269669 | GEO | 2025/03/28

REPOSITORIES: GEO

Json Xml

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

Unknown Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis.
| S-EPMC12165814 | biostudies-literature
Genomics Phase Ib/II Study of Azacitidine, Venetoclax and Magrolimab in Adult Patients with Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia
| PRJNA1123202 | ENA
Unknown Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
| S-EPMC9508061 | biostudies-literature
Unknown Azacitidine in combination with HAG for newly diagnosed and relapsed/refractory AML: a prospective cohort study.
| S-EPMC12031814 | biostudies-literature
Unknown Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial.
| S-EPMC10149010 | biostudies-literature
Unknown Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.
| S-EPMC8714726 | biostudies-literature
Unknown A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia.
| S-EPMC10046472 | biostudies-literature
Unknown A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
| S-EPMC10100228 | biostudies-literature
Unknown Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
| S-EPMC11978487 | biostudies-literature
Unknown Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
| S-EPMC6158762 | biostudies-literature